Sigyn Therapeutics, Inc. Sigyn Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Sigyn Therapy™
  • Drug Enhancement Technologies
    • Overview
    • ImmunePrep™
    • ChemoPrep™
    • ChemoPure™
  • News
    • Press Releases
    • Presentations
    • Resources
  • Media
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Email Alerts
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
  • CEO Notes

Press Releases

News

News

  • Press Releases
  • Presentations
  • Resources
Oct 04, 2023 8:30am EDT

Sigyn Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity

Sep 06, 2023 8:00am EDT

Sigyn Therapeutics to Present at Today’s Emerging Growth Conference and Tomorrow at the National Investment Bankers Association Conference

Aug 14, 2023 4:30pm EDT

Sigyn Therapeutics Reports Second Quarter 2023 Financial Results

Aug 08, 2023 10:30am EDT

Sigyn Therapeutics to Present at Tomorrow’s Emerging Growth Conference

Jul 31, 2023 8:35am EDT

Sigyn Therapeutics to Present at the OTCQB Venture Virtual Investor Conference on August 3rd

May 17, 2023 7:00am EDT

Sigyn Therapeutics Discloses “DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES” Patent Submission and Related ImmunePrep™ Trademark Application

May 16, 2023 7:30am EDT

Sigyn Therapeutics Reports First Quarter 2023 Financial Results

Apr 11, 2023 8:30am EDT

Sigyn Therapeutics™ Announces Appointment of Annette Marleau, Ph.D. as Chief Scientific Officer

Mar 31, 2023 9:45am EDT

Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K

Nov 15, 2022 7:30am EST

Sigyn Therapeutics Announces Third Quarter 2022 Financial Results

  • 1
  • 2
  • 3
  • 4
  • 5
  • Next
RSS
© 2023 Sigyn Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap